Cubist Systematic Strategies LLC grew its position in Zoetis Inc (NYSE:ZTS) by 3,290.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,652 shares of the company’s stock after purchasing an additional 144,268 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Zoetis were worth $16,871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Zoetis by 2.2% in the first quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after acquiring an additional 795,558 shares during the period. Vanguard Group Inc. grew its position in shares of Zoetis by 1.0% during the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after buying an additional 346,167 shares in the last quarter. Polen Capital Management LLC grew its position in shares of Zoetis by 0.9% during the second quarter. Polen Capital Management LLC now owns 10,188,554 shares of the company’s stock worth $1,156,299,000 after buying an additional 86,364 shares in the last quarter. FMR LLC grew its position in shares of Zoetis by 12.2% during the first quarter. FMR LLC now owns 8,127,931 shares of the company’s stock worth $818,239,000 after buying an additional 882,183 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Zoetis by 1.0% during the second quarter. Northern Trust Corp now owns 5,963,894 shares of the company’s stock worth $676,842,000 after buying an additional 58,435 shares in the last quarter. Institutional investors and hedge funds own 90.09% of the company’s stock.
In other news, insider Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $113.09, for a total transaction of $692,450.07. Following the sale, the insider now owns 46,812 shares of the company’s stock, valued at approximately $5,293,969.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the sale, the executive vice president now directly owns 48,877 shares in the company, valued at approximately $6,022,623.94. The disclosure for this sale can be found here. Insiders have sold a total of 34,332 shares of company stock worth $4,163,091 in the last ninety days. Insiders own 0.29% of the company’s stock.
A number of brokerages have recently commented on ZTS. Argus set a $140.00 price objective on Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Stifel Nicolaus set a $140.00 price objective on Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and upped their price target for the company from $111.00 to $120.00 in a report on Monday, July 1st. They noted that the move was a valuation call. Barclays upped their price target on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Goldman Sachs Group assumed coverage on Zoetis in a report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 price target for the company. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $120.94.
Shares of ZTS stock traded up $1.58 on Friday, hitting $125.85. 710,223 shares of the company’s stock traded hands, compared to its average volume of 2,059,244. The stock has a market capitalization of $59.97 billion, a price-to-earnings ratio of 40.21, a P/E/G ratio of 3.09 and a beta of 0.87. Zoetis Inc has a one year low of $78.90 and a one year high of $130.08. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The company’s fifty day simple moving average is $123.64 and its 200 day simple moving average is $109.75.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 EPS. As a group, sell-side analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Dividend Reinvestment Plan (DRIP)
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.